Atlas Trials

Tislelizumab in Combination with Chemotherapy ± Radiotherapy for Extensive-Stage Oligometastatic Small Cell Lung Cancer.

Clinical trial NCT06851819 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06851819
Sponsor
Hebei Medical University Fourth Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Small Cell Lung Cancer Extensive Stage
Start date
2025-03-01
Primary completion
2027-01-31
Enrollment
64

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.